LONA

#4473
LeonaBio, Inc. Common Stock
9.68 USD
+6.73%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
9.27
9.68
Годовой диапазон
4.22
14.19
Дневное изменение
+6.73%
Месячное изменение
+26.21%
6-месячное изменение
+43.62%
Годовое изменение
+43.62%
Предыдущее закрытие
9.07
Открыть
9.27
Bid
Ask
Минимум
9.27
High
9.68
Объем
4
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 38.18 M
  • Employee 19
  • Founded 2011
  • CEO N/A
  • Website www.leonabio.com
  • Headquarter Washington, United States
  • FIGI BBG00C77LX40
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты

LeonaBio Inc

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.